| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910925 | Lung Cancer | 2014 | 24 Pages |
Abstract
Saracatinib at a dose of 175Â mg/day by mouth is well tolerated. However, the PFS rate observed at the pre-planned interim analysis did not meet the criteria for additional enrollment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Julian R. Molina, Nathan R. Foster, Thanyanan Reungwetwattana, Garth D. Nelson, Andrew V. Grainger, Preston D. Steen, Philip J. Stella, Randolph Marks, John Wright, Alex A. Adjei,